Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 5/20 | 0.70 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.59 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10073873 | 1.00 | TRPM8 (0.70) | TRPM8TRPV1EPHX1MEN1ALDH1A1 | |
| SCHEMBL2628676 | 0.89 | TRPM8 (0.69) | TRPM8TRPV1EPHX1MEN1KMT2A | |
| SCHEMBL4817319 | 0.86 | TRPM8 (0.75) | TRPM8TRPV1EPHX1MEN1ALDH1A1 | |
| SCHEMBL10073486 | 0.86 | TRPM8 (0.75) | TRPM8TRPV1EPHX1MEN1ALDH1A1 | |
| SCHEMBL2628672 | 0.86 | TRPM8 (0.75) | TRPM8TRPV1EPHX1MEN1ALDH1A1 | |
| SCHEMBL4820732 | 0.86 | TRPM8 (0.75) | TRPM8TRPV1EPHX1MEN1ALDH1A1 | |
| SCHEMBL10073506 | 0.85 | TRPM8 (0.73) | TRPM8TRPV1EPHX1MEN1ALDH1A1 | |
| SCHEMBL2628747 | 0.85 | TRPM8 (0.73) | TRPM8TRPV1EPHX1MEN1HTT | |
| SCHEMBL2628777 | 0.85 | TRPM8 (0.73) | TRPM8TRPV1EPHX1MEN1KMT2A | |
| SCHEMBL2628758 | 0.85 | TRPM8 (0.73) | TRPM8TRPV1EPHX1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120045448-A1 | TRP-P8 ACTIVE COMPOUNDS AND THERAPEUTIC TREATMENT METHODS | GENENTECH, INC. (US) | 2012-02-23 | — | — | US | claimed |
| US-7893072-B2 | Cool-genic compounds as anticarcinogenic agents promoting apoptosis and inhibit angiogenesis; antiproliferative agents | GENENTECH, INC. (US) | 2011-02-22 | — | — | US | claimed |
| US-20120045448-A1 | TRP-P8 ACTIVE COMPOUNDS AND THERAPEUTIC TREATMENT METHODS | GENENTECH, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-7893072-B2 | Cool-genic compounds as anticarcinogenic agents promoting apoptosis and inhibit angiogenesis; antiproliferative agents | GENENTECH, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20050090514-A1 | Trp-p8 active compounds and therapeutic treatment methods | GENENTECH, INC. | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090514-A1 | Trp-p8 active compounds and therapeutic treatment methods | TSG101, TP53, BAX | TRPM8 28/4885TRPV1 14/4885EPHX1 1033/4885 |
| US-20120045448-A1 | TRP-P8 ACTIVE COMPOUNDS AND THERAPEUTIC TREATMENT METHODS | TSG101, TP53, BAX | TRPM8 28/4885TRPV1 14/4885EPHX1 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.